Six things to know:
1. The Department of Justice accused Heritage of conspiring with competitors to fix prices, rig bids and allocate customers for glyburide between April 2014 and December 2015.
2. Heritage will pay more than $7 million to resolve the civil and criminal charges related to the price-fixing.
3. The Justice Department is investigating the entire generic drug industry for price fixing, and under the terms of the agreement, Heritage will cooperate with that probe.
4. Jeffrey Glazer and Jason Malek, two former Heritage executives, already pleaded guilty to price-fixing conspiracy charges. Their sentencing hearings are scheduled for September.
5. “American consumers have the right to generic drugs sold at prices set by competition, not collusion,” said Assistant Attorney General Makan Delrahim of the Justice Department. “Heritage and its co-conspirators cheated and exploited vulnerable American patients to pad their bottom line.”
6. Heritage said that it has revamped its leadership team in the wake of the allegations. “We are pleased to put these issues behind us and focus on Heritage’s future,” William Marth, global president and CEO of the Heritage Group, North America and Europe, said in a news release.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
J&J to cut 61 jobs in New Jersey
Mallinckrodt to spin off generics unit
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.